_______________________________________
FREE Daily Stock Alerts From CRWEWallStreet.com
_______________________________________
Dynamic Response Group, Inc. (OTCBB: DRGZ) announced today results for the 3rd quarter accounts payable and accrued expenses decreased over a million dollars and the Company’s net loss also reduced by 1.4 million dollars over the nine months ending September 30, 2009. Other Income increased over 500,000 dollars over the same nine month period. Cash Flow improved by 61,000 dollars as compared to the same period last year.
Power3 Medical Products, Inc. (OTCBB: PWRM), announced that the company made significant advances in the technology for their BC-SeraPro serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.
Web Site: http://www.Power3Medical.com
OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to be well-tolerated, and that there were no significant overlapping toxicities with bevacizumab.
Aquentium, Inc. (OTCBB: AQNM) a publicly traded company with a focus on “green technologies” is pleased to announce their high speed ozone hand dryer as a solution for increased bathroom sanitation and bacteria and virus protection for schools and universities. The hand dryer combines high speed drying with ozone in order to sanitize the air and keep the blowers inside the dryer free from bacteria.
Website: http://www.aquentium.com
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of Merkel cell carcinoma (MCC). Meaningful evidence of anticancer activity has been noted among the limited number of patients with MCC who have received IMGN901. These findings were reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC could be a potential registration path for IMGN901.
************Advertisement************
.png)
.png)
.png)
************************************
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings, Inc. (CRWE.OB) is being paid 100,000 restricted shares for public relations services for Aquentium Inc. (AQNM).
